Equillium, Inc. Files 8-K for Other Events
Ticker: EQ · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1746466
| Field | Detail |
|---|---|
| Company | Equillium, INC. (EQ) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulatory
TL;DR
Equillium filed an 8-K, but no juicy details yet.
AI Summary
Equillium, Inc. filed an 8-K on June 4, 2024, to report other events and financial statements. The company, incorporated in Delaware, is based in La Jolla, California, and operates in the pharmaceutical preparations sector. The filing does not contain specific financial figures or details about the 'other events' reported.
Why It Matters
This filing indicates Equillium, Inc. is making a regulatory disclosure, but lacks specific details on the events or financial statements being reported.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate financial or operational impact revealed.
Key Players & Entities
- Equillium, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
- La Jolla, California (location) — Principal Executive Offices
- 2223 Avenida de la Playa Suite 105 (address) — Business Address
FAQ
What specific 'Other Events' are being reported by Equillium, Inc. in this 8-K filing?
The filing indicates 'Other Events' are being reported, but does not specify what those events are.
What financial statements are being included with this 8-K filing?
The filing states that 'Financial Statements and Exhibits' are included, but does not detail the specific financial statements.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 4, 2024.
What is Equillium, Inc.'s principal executive office address?
Equillium, Inc.'s principal executive office is located at 2223 Avenida de la Playa Suite 105, La Jolla, California.
What is Equillium, Inc.'s standard industrial classification?
Equillium, Inc.'s standard industrial classification is Pharmaceutical Preparations [2834].
Filing Stats: 1,280 words · 5 min read · ~4 pages · Grade level 11.5 · Accepted 2024-06-04 08:00:55
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share EQ Nasdaq Capital Market
Filing Documents
- d842173d8k.htm (8-K) — 53KB
- d842173dex991.htm (EX-99.1) — 38KB
- g842173ex99_1s10g1.jpg (GRAPHIC) — 95KB
- g842173ex99_1s11g1.jpg (GRAPHIC) — 93KB
- g842173ex99_1s12g1.jpg (GRAPHIC) — 52KB
- g842173ex99_1s13g1.jpg (GRAPHIC) — 84KB
- g842173ex99_1s14g1.jpg (GRAPHIC) — 94KB
- g842173ex99_1s15g1.jpg (GRAPHIC) — 93KB
- g842173ex99_1s16g1.jpg (GRAPHIC) — 95KB
- g842173ex99_1s17g1.jpg (GRAPHIC) — 111KB
- g842173ex99_1s18g1.jpg (GRAPHIC) — 126KB
- g842173ex99_1s19g1.jpg (GRAPHIC) — 47KB
- g842173ex99_1s1g1.jpg (GRAPHIC) — 74KB
- g842173ex99_1s20g1.jpg (GRAPHIC) — 103KB
- g842173ex99_1s21g1.jpg (GRAPHIC) — 53KB
- g842173ex99_1s22g1.jpg (GRAPHIC) — 57KB
- g842173ex99_1s23g1.jpg (GRAPHIC) — 57KB
- g842173ex99_1s24g1.jpg (GRAPHIC) — 90KB
- g842173ex99_1s25g1.jpg (GRAPHIC) — 69KB
- g842173ex99_1s26g1.jpg (GRAPHIC) — 93KB
- g842173ex99_1s27g1.jpg (GRAPHIC) — 95KB
- g842173ex99_1s28g1.jpg (GRAPHIC) — 82KB
- g842173ex99_1s29g1.jpg (GRAPHIC) — 129KB
- g842173ex99_1s2g1.jpg (GRAPHIC) — 166KB
- g842173ex99_1s30g1.jpg (GRAPHIC) — 111KB
- g842173ex99_1s31g1.jpg (GRAPHIC) — 63KB
- g842173ex99_1s3g1.jpg (GRAPHIC) — 53KB
- g842173ex99_1s4g1.jpg (GRAPHIC) — 126KB
- g842173ex99_1s5g1.jpg (GRAPHIC) — 122KB
- g842173ex99_1s6g1.jpg (GRAPHIC) — 131KB
- g842173ex99_1s7g1.jpg (GRAPHIC) — 89KB
- g842173ex99_1s8g1.jpg (GRAPHIC) — 90KB
- g842173ex99_1s9g1.jpg (GRAPHIC) — 94KB
- 0001193125-24-153667.txt ( ) — 4143KB
- eq-20240604.xsd (EX-101.SCH) — 3KB
- eq-20240604_lab.xml (EX-101.LAB) — 18KB
- eq-20240604_pre.xml (EX-101.PRE) — 11KB
- d842173d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Equillium, Inc. Dated: June 4, 2024 By: /s/ Jason A. Keyes Jason A. Keyes Chief Financial Officer